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The efficacy of paclitaxel and cisplatin combinations has been
shown in two recent phase III trials (McGuire et al, 1996; Piccart
et al, 1997), and this combination is currently widely used as the
primary regimen for ovarian carcinoma. Docetaxel is another
actively studied taxane. In vitro studies have shown that compared
with paclitaxel, it has higher intracellular accumulation and
binding to microtubules, as well as lower efflux and dissociation
from microtubules (Riou et al, 1994; Lavelle et al, 1995). Phase I
trials on docetaxel–cisplatin treatments are also ongoing. This
combination appears promising in non-small-cell lung cancer and
in a few other solid tumour types, including colorectal, head and
neck, gastric and breast cancer (Burris et al, 1995). Preliminary
results from phase II clinical trials on the use of docetaxel in
advanced ovarian cancer have confirmed the data obtained from
preclinical studies (Kaye et al, 1995). Cisplatin is the most e ffec-
tive single chemotherapeutic agent in the treatment of ovarian
carcinoma (Thigpen et al, 1989; Advanced Ovarian Cancer
Trialists Group, 1991). The role of docetaxel in the management 
of this disease will, therefore, depend on the cytotoxic e ffect
achieved with docetaxel–cisplatin therap y.
We have recently studied the sensitivity of cisplatin, paclitaxel
and docetaxel in seven epithelial ovarian carcinoma cell lines
using a clonogenic assay. The IC50 values of these drugs varied
between 0.3 and 1.5pM, 0.4 and 3.4nMand 0.2 and 2.3nMrespec-
tively (Engblom et al, 1996, 1997). On a molar basis, docetaxel
was more cytotoxic than paclitaxel in six out of seven cell lines.
The purpose of this study was to make a comparison between
combinations of cisplatin–paclitaxel and of cisplatin–docetaxel in
ovarian carcinoma cell lines, and to assess the types of interaction
obtained. To our knowledge, comparative in vitro studies have not
been previously published.
MATERIALS AND METHODS
Cell lines
Seven ovarian carcinoma cell lines were tested in this stud y. The
cell lines used, their histological type, plating e fficiencies (PE) and
passages used are listed in  Table 1. The SK-O V-3 and the CAO V-
3 cell lines (Fogh et al, 1977; Untch et al, 1994) were obtained
from the American Type Culture Collection (Rocville, MD, USA),
and five cell lines (UT-OC-1, U T-OC-2, U T-OC-3, U T-OC-4 and
UT-OC-5) have been established recently at the University of
Turku by the author for correspondence. The U T-OC-5 cell line
was derived from a metastatic omental tumou r, whereas the other
cell lines were established from primary tumours. The donor of 
the UT-OC-2 cell line had been treated with four courses of
vincristine, doxorubicin and cyclophosphamide and radiotherapy
for pulmonary metastases before the cell line was established from
a primary tumour outside the radiation field. The donors of the
UT-OC-4 and U T-OC-5 cell lines had received pelvic radiotherapy
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for cervical cancer 30 and 5 years before the diagnosis of ovarian
carcinoma. The donors of the UT-OC-1 and UT-OC-3 cell lines
had not received any cytotoxic therapy before the establishment of
the cell lines.
Cell culture
Before the experiments, the cells were kept in logarithmic growth
in T25 culture flasks by passing weekly in Dulbecco’s modified
Eagle’s minimal essential medium (DMEM) containing 2 mM
L-glutamine, 1% non-essential amino acids, 100 U ml–1 strepto-
mycin, 100 U ml–1 penicillin and 10% fetal bovine serum (FBS).
Cells in mid-logarithmic growth (40–60% confluence) were used
for the experiments and fed with fresh medium on the day before
plating.
Drug preparation
Cisplatin (Platinol) 0.5 mg ml–1 was diluted with growth medium
to get a stock solution of 100 mg ml–1. Final cisplatin dilutions of
0.05–0.6 mg ml–1 were used, and new stock solutions were made
for each experiment. Paclitaxel (Taxol, kindly provided by Bristol-
Myers Squibb) was initially dissolved in 0.9% sodium chloride to
get a solution of 0.1 mM. Stock solutions were prepared in Ham’s
F-12 medium containing 10% FBS to obtain a solution of 100 nM,
and stored at –40°C. Final dilutions of 0.4–5 nM paclitaxel were
used for the experiments. Docetaxel (Taxotere, 807.9 mg, kindly
provided by Rhone-Poulenc Rorer) was diluted in 1 ml of ethanol
to obtain a stock solution of 0.1 mM and stored at –40°C. These
solutions were further diluted in sterile water to obtain a solution
of 100 nM immediately before each experiment. Final dilutions of
0.3–4 nM docetaxel were used for the experiments. We have previ-
ously studied the sensitivity of cisplatin, paclitaxel and docetaxel
in these cell lines (Engblom et al, 1996, 1997). The IC50 values
obtained in these experiments are given in Table 1 and were used
as the basis of drug concentrations used in this study. The pacli-
taxel concentrations used in this study corresponded to 25–100%
of the IC50 values of the cell lines. The docetaxel concentration
varied from 25% to 150% of the IC50 value.
Clonogenic assay
The 96-well plate clonogenic assay based on limiting dilutions
was used. The assay has been described earlier in detail (Grènman
et al, 1989; Rantanen et al, 1994). The cells were harvested with
trypsin-EDTA to obtain a single-cell suspension, counted and
diluted in Ham’s F-12 medium containing 15% FBS. The number
of cells plated per well was adjusted according to the PE of the cell
line. The desired concentrations of paclitaxel or docetaxel were
added in a stock solution containing 4167 cells ml–1, and diluted in
25 ml of growth medium. A concentration of two cells per well is
achieved by applying 100 ml of this stock solution to each well of
the 96-well plate. The desired cisplatin concentrations along with
the same paclitaxel or docetaxel concentration as on the day before
were added in 100 ml of growth medium after the plates had been
incubated for 24 h. All the drugs were allowed to stay on the plates
throughout the whole incubation period. The plates were incu-
bated at 37°C with 5% carbon dioxide for 4 weeks, after which the
number of wells containing coherent, living colonies, consisting of
32 cells or more, was counted using an inverted phase-contrast
microscope.
Data analysis
PE was calculated by the formula PE = –ln (number of negative
wells/total number of wells)/number of cells plated per well
(Thilly et al, 1980). Fraction survival data were fitted to the linear
quadratic model, F = exp [–(aD+bD2)] and a microcomputer
program was used to obtain the area under the curve (AUC) by
numerical integration. The simultaneous effects of cisplatin and
paclitaxel or docetaxel were determined as the ratio between the
AUC for cisplatin plus paclitaxel or docetaxel, divided by the
AUC for cisplatin alone. This AUC ratio was compared with the
surviving fraction (SF) after the indicated dose of paclitaxel or
docetaxel alone. Comparison of the AUC ratio and the SF value
was made using the Student’s t-test. The influence of the taxane
concentration on the amount of additive or supra-additive cyto-
toxic effect was tested by one-way analysis of variance (ANOVA).
The schedule of the drug administration is important and the
achieved growth inhibition can vary from a subadditive to a supra-
additive effect. To describe the type of interaction, we have used
the term additive of the sum of individual effects. The term supra-
additive is used if the combined effect exceeds the sum of
individual effects. Some authors use the term synergy, which we
have interpreted here as supra-additivity.
RESULTS
Cisplatin and taxanes had either an additive or supra-additive
growth inhibitory effect in all cell lines studied. The type and
magnitude of growth inhibition varied between individual cell
lines. In most of the cell lines, higher taxane concentrations
Table 1 Histological type, the passages used and the plating efficiency (PE) of the seven ovarian carcinoma cell lines and chemosensitivity of these cell lines
to cisplatin, paclitaxel and docetaxel expressed as IC50 values, corresponding to the drug concentration causing 50% inhibition of clonogenic survival
Cell line Histological type Passages used Plating efficiency Cisplatina Paclitaxela Docetaxelb
IC50 ± s.d. (pM)I C 50 ± s.d. (nM)I C 50 ± s.d. (nM)
UT-OC-1 Mucinous 24–42 0.05–0.06 0.6 ± 0.2 1.4 ± 0.1 0.8 ± 0.1
UT-OC-2 Endometrioid 10–24 0.06–0.09 0.3 ± 0.1 2.0 ± 0.2 2.3 ± 0.3
UT-OC-3 Serous 20–37 0.09–0.2 0.7 ± 0.1 1.3 ± 0.1 1.0 ± 0.1
UT-OC-4 Endometrioid 30–37 0.06–0.1 1.0 ± 0.2 1.0 ± 0.1 0.5 ± 0.1
UT-OC-5 Serous 14–18 0.05–0.1 1.2 ± 0.2 1.4 ± 0.1 1.2 ± 0.2
SK-OV-3 Epithelial 32–44 0.2–0.4 1.5 ± 0.1 3.4 ± 0.2 1.3 ± 0.2
CAOV-3 Papillary 41–48 0.08–0.2 0.9 ± 0.1 0.4 ± 0.1 0.2 ± 0.1
aEngblom et al (1996); bEngblom et al (1997).288 P Engblom et al
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increased the extent of supra-additive effect. In some cell lines,
lower drug concentrations caused an additive effect, whereas
higher concentrations were supra-additive. Furthermore, on a
molar basis, docetaxel–cisplatin combinations had more
pronounced cytotoxic effects than paclitaxel–cisplatin combina-
tions. A supra-additive effect was seen more frequently with a
cisplatin–docetaxel combination than with a cisplatin–paclitaxel
combination (Tables 2 and 3).
The type of interaction after paclitaxel and cisplatin and the
statistical significance of supra-additivity is presented in Table 2.
Dose dependency of the magnitude of the interaction is presented
in Table 4. All paclitaxel concentrations used concomitantly with
Table 2 Effects of paclitaxel on clonogenic survival of seven ovarian carcinoma cell lines. Paclitaxel was used as a
single agent and concomitantly with cisplatin
Cell line Paclitaxel Cisplatin dose Sa
paclitaxel AUC ratiob P-value
dose (nM)( mg ml–1)
UT-OC-1 0.6 0.05–0.15 0.91 ± 0.07 0.89 ± 0.03 0.45 (A)
0.8 0.78 ± 0.04 0.80 ± 0.03 0.30 (A)
1.0 0.68 ± 0.03 0.59 ± 0.03 0.0003 (SA)
UT-OC-2 0.8 0.01–0.1 0.90 ± 0.10 0.87 ± 0.08 0.69 (A)
1.0 0.88 ± 0.06 0.88 ± 0.08 0.97 (A)
2.0 0.72 ± 0.05 0.72 ± 0.08 0.91 (A)
UT-OC-3 0.6 0.05–0.4 0.94 ± 0.02 1.01 ± 0.06 0.58 (A)
0.8 0.77 ± 0.11 0.86 ± 0.12 0.49 (A)
1.0 0.67 ± 0.11 0.70 ± 0.08 0.68 (A)
UT-OC-4 0.4 0.2–0.6 1.00 ± 0.04 0.92 ± 0.05 0.0046 (SA)
0.6 0.93 ± 0.02 0.84 ± 0.05 0.0021 (SA)
0.8 0.63 ± 0.02 0.33 ± 0.05 0.0001 (SA)
UT-OC-5 0.6 0.2–0.5 0.97 ± 0.02 0.85 ± 0.05 0.071 (A)
0.8 0.88 ± 0.04 0.63 ± 0.05 0.011 (SA)
1.0 0.68 ± 0.08 0.42 ± 0.06 0.056 (A)
SK-OV-3 1.5 0.3–0.6 0.95 ± 0.05 0.95 ± 0.03 0.021 (SA)
2.0 0.91 ± 0.04 0.76 ± 0.03 0.0008 (SA)
3.0 0.66 ± 0.03 0.51 ± 0.06 0.036 (SA)
CAOV-3 0.1 0.1–0.5 0.96 ± 0.08 0.91 ± 0.07 0.11 (A)
0.2 0.93 ± 0.06 0.83 ± 0.12 0.25 (A)
0.3 0.81 ± 0.03 0.68 ± 0.05 0.0065 (SA)
aClonogenic survival after the indicated paclitaxel dose; bthe ratio between the AUC for cisplatin plus paclitaxel, divided by
the AUC for cisplatin alone. P-values were calculated using the Student’s t-test. A, additive effect; SA, supra-additive
effect.
Table 3 Effects of docetaxel on clonogenic survival of seven ovarian carcinoma cell lines. Docetaxel was used as a
single agent and concomitantly with cisplatin
Cell line Docetaxel Cisplatin dose Sa
docetaxel AUC ratiob P-value
dose (nM)( mg ml–1)
UT-OC-1 0.2 0.005–0.15 1.00 ± 0.03 0.96 ± 0.05 0.15 (A)
0.5 0.89 ± 0.03 0.81 ± 0.05 0.039 (SA)
0.8 0.65 ± 0.06 0.57 ± 0.04 0.019 (SA)
UT-OC-2 0.8 0.01–0.1 0.79 ± 0.07 0.97 ± 0.05 0.0087 (SA)
1.0 0.73 ± 0.09 0.74 ± 0.07 0.19 (A)
1.5 0.68 ± 0.03 0.68 ± 0.05 0.87 (A)
UT-OC-3 0.5 0.05–0.4 0.77 ± 0.04 0.71 ± 0.02 0.021 (SA)
0.8 0.72 ± 0.05 0.53 ± 0.03 0.0001 (SA)
1.0 0.68 ± 0.04 0.45 ± 0.03 0.0001 (SA)
UT-OC-4 0.3 0.2–0.6 0.80 ± 0.03 0.71 ± 0.04 0.0005 (SA)
0.4 0.64 ± 0.05 0.48 ± 0.08 0.0001 (SA)
0.5 0.53 ± 0.08 0.37 ± 0.07 0.0001 (SA)
UT-OC-5 0.4 0.2–0.5 0.83 ± 0.03 0.74 ± 0.03 0.0030 (SA)
0.6 0.75 ± 0.04 0.64 ± 0.03 0.0006 (SA)
0.8 0.64 ± 0.04 0.51 ± 0.003 0.0017 (SA)
SK-OV-3 0.8 0.3–0.6 0.94 ± 0.04 0.80 ± 0.04 0.0002 (SA)
1.0 0.90 ± 0.04 0.75 ± 0.05 0.0002 (SA)
1.3 0.81 ± 0.05 0.57 ± 0.07 0.0001 (SA)
CAOV-3 0.1 0.1–0.5 0.95 ± 0.04 0.92 ± 0.07 0.10 (A)
0.2 0.92 ± 0.04 0.76 ± 0.12 0.0097 (SA)
0.3 0.69 ± 0.05 0.50 ± 0.08 0.015 (SA)
aClonogenic survival after the indicated docetaxel dose; bratio between the AUC for cisplatin plus docetaxel divided by the
AUC for cisplatin alone. P-values were calculated using the Student’s t-test. A, additive effect; SA, supra-additive effect.Concomitant use of taxanes and cisplatin in vitro289
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cisplatin caused a supra-additive growth inhibitory e ffect in the
UT-OC-4 and SK-O V-3 cell lines. Additive effect was found with
all tested paclitaxel concentrations in U T-OC-2 and U T-OC-3
cells. In CAOV-3 cells, the combined effect was additive (P-values
0.11 and 0.25) when cisplatin was added to 0.1 or 0. 2nMpacli-
taxel, which corresponds to 50% or 100% of the previously deter-
mined IC50 concentration. In contrast, 0. 3nMpaclitaxel caused a
clear supra-additive  (P = 0.0065) effect. In UT-OC-1 cells, an
additive growth inhibitory effect (P-values 0.45 and 0.30) was
noticed with 0.6 and 0.8nMpaclitaxel, corresponding to 43% and
57% of the IC50 dose (Table 2). The UT-OC-1 cells showed a clear
supra-additive effect when 1.0nMof paclitaxel was combined with
cisplatin. In cell lines showing supra-additivity with lower pacli-
taxel doses, the increasing paclitaxel dose resulted in increased
supra-additivity. In the UT-OC-1, U T-OC-4 and SK-O V-3 cell
lines, the degree of supra-additivity was found to be directly corre-
lated to the dose of paclitaxel and this correlation was statistically
significant (Table 4). The fitted survival curves of the seven
ovarian carcinoma cell lines with three various paclitaxel doses
combined with cisplatin are shown in Figure 1.
The type of interaction after docetaxel and cisplatin and the
statistical significance of supra-additivity is shown in  Table 3, and
the dose dependency of interaction is presented in  Table 4. In four
cell lines (SK-OV-3, UT-OC-3, U T-OC-4 and U T-OC-5), a supra-
additive effect was found after simultaneous use of cisplatin with
all tested docetaxel concentrations. The lowest docetaxel dose
used in the CAOV-3 and UT-OC-1 cells, corresponding to 50%
and 25%, respectively, of the IC 50 doses of the cell lines, caused a
pure additive effect (P-values 0.10 and 0.15), whereas with a
higher docetaxel dose supra-additivity was found. The U T-OC-2
cell line was an exception because the combined effect was supra-
additive with the lowest docetaxel dose, and additive with the two
higher doses (Table 3). The degree of supra-additivity was dose
dependent in SK-OV-3, UT-OC-3 and U T-OC-4 cell lines.
Increasing the docetaxel dose resulted in a clearer supra-additive
effect. The same phenomenon was noticed also in CAO V-3 and
UT-OC-1 cells, though in these cell lines the lowest docetaxel dose
caused a purely additive effect (Table 3). The fitted survival curves
of the seven cell lines after concomitant exposure to docetaxel and
cisplatin are shown Figure 1.
DISCUSSION
In this study, we demonstrated a supra-additive or additive 
growth-inhibitory effect when human ovarian carcinoma cells
were exposed to paclitaxel or docetaxel concomitantly with
cisplatin. This effect was found to be dose dependent with the
combination of paclitaxel and cisplatin in three cell lines and with
the combination of docetaxel and cisplatin in four out of seven cell
lines (Table 4). The UT-OC-2 cell line was an exception; simulta-
neous docetaxel and cisplatin caused a clear supra-additive e ffect
with the lowest docetaxel dose and an additive e ffect with the two
higher doses. In our previous study, we have shown that clono-
genic cell survival after paclitaxel or docetaxel exposure clearly
correlated in six out of seven ovarian carcinoma cell lines
(Engblom et al, 1997). The only exception was the U T-OC-2 cell
line. This result was consistent in repeated experiments. On a
molar basis, all seven ovarian cell lines showed more pronounced
supra-additivity with the combination of docetaxel and cisplatin
compared with paclitaxel and cisplatin.
The effects of paclitaxel in combination with cisplatin were
initially reported by Citardi and colleagues in 1990 in mouse
leukaemia L1210 cells. They demonstrated the superiority of
paclitaxel given before cisplatin compared with other regimens
(Citardi et al, 1990). In ovarian cancer cell lines, the decrease of
cell viability was significantly greater with the combination of
paclitaxel and cisplatin compared with exposure to a single drug
(Untch et al, 1994).  With human ovarian carcinoma cells, additive
or supra-additive effect was found when the cells were exposed to
paclitaxel before cisplatin. Conversel y, if cisplatin was given first,
antagonism was observed (Parker et al, 1993; Jekunen et al, 1994;
Kiyozuka et al, 1995). In the current experiments, an additive or
supra-additive inhibitory e ffect was seen in all cell lines when the
taxane were administered concomitantly with cisplatin. This is in
line with previously published reports showing an additive
(Saunders et al, 1992; Jekunen et al, 1994) or supra-additive
(Parker et al, 1993) e ffect with the cisplatin–paclitaxel combina-
tion in ovarian cell lines. The growth inhibitory e ffect of docetaxel
combined with cytotoxic agents has not been studied as widely as
that of paclitaxel. In a study with human breast carcinoma cells, an
additive or supra-additive e ffect was noticed after cells pretreated
with edatrexate were treated with docetaxel. Howeve r, antagonism
was evident when the schedule was reversed (Chou et al, 1996). In
the present study, we demonstrated a supra-additive or additive
growth inhibitory effect when docetaxel was given concomitantly
with cisplatin. Moreover, on a molar basis, this combination was
more effective than the combination of paclitaxel and cisplatin.
The type and degree of the growth inhibitory e ffect varied with
different doses of the taxanes. Increasing paclitaxel doses resulted
in increasing supra-additivity in three out of seven cell lines. The
same kind of dose-dependent interaction was found in the breast
cancer cell lines (Koechli et al, 1993). The dose dependency of 
the cisplatin–docetaxel combination was even more pronounced
because the degree of supra-additivity was dose dependent in three
cell lines. In an additional two cell lines, the lowest docetaxel dose
had an additive effect and higher doses had a supra-additive
growth inhibitory effect.
It has been demonstrated in several studies that on a molar basis
docetaxel is more potent than paclitaxel as a single drug (Kelland
et al, 1992; Riou et al, 1992; Hill et al, 1994; Engblom et al, 1997).
In the present stud y, a greater supra-additive e ffect was achieved
with the combination of docetaxel and cisplatin compared with the
Table 4  The dose dependence of additive and supra-additive cytotoxic
effect. The influence of the concentration was tested by one-way analysis of
variance (Anova) and the P-values after cisplatin plus paclitaxel and cisplatin
plus docetaxel are listed below. A statistically significant direct correlation
between increasing the taxane dose and the amount of synergy is found
when P is < 0.05
Cell line  Cisplatin plus paclitaxel  Cisplatin plus docetaxel
UT-OC-1 0.0032 0.53
UT-OC-2 0.88 a
UT-OC-3 0.84 0.0001
UT-OC-4 0.0001 0.0050
UT-OC-5 0.24 0.24
SK-OV-3 0.015 0.0004
CAOV-3 0.59 0.027
aUT-OC-2 cell line was an exception because the combined effect was supra-
additive with the lowest docetaxel dose and additive with the two higher
doses.290 P Engblom et al
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Figure 1 Effects of simultaneous use of cisplatin and paclitaxel or docetaxel. Fitted cisplatin curves for the seven ovarian carcinoma cell lines without
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combination of paclitaxel and cisplatin. Studies evaluating the
mechanism of action of these two taxanes have shown that, in
comparison with paclitaxel, docetaxel is slightly more active as 
a tubulin assembly promoter and microtubule stabilizer, and
approximately twofold more potent as an inhibitor of microtubule
depolymerization (Gueritte-Voegelein et al, 1991). Furthermore,
the effective affinity of docetaxel for the microtubule binding site
is 1.9-fold greater than that of paclitaxel (Diaz et al, 1993). These
differences in mechanism of action may explain the differences in
the cytotoxic effect achieved with concomitant use of cisplatin and
these two taxanes.
Peak plasma concentrations achieved with a 24-h paclitaxel
infusion have ranged from 0.23 to 0.43 mM, and with a 3-h infusion
from 2.5 to 4.3 mM (Huizing et al, 1993). After a 1-h infusion, the
peak plasma concentration for docetaxel has been 4.46 mM (Hino
et al, 1995), and for cisplatin 2.5 mg ml–1 (Gullo et al, 1980). The
current experiments were performed using paclitaxel concentra-
tions of 0.1–3 nM, docetaxel doses of 0.1–1.5 nM and cisplatin
doses of 0.01–0.6 mg ml–1, which were clearly below the peak
plasma concentrations achieved for these drugs. In vitro, the dura-
tion of both paclitaxel (Rowinsky et al, 1988; Arbuck et al, 1993;
Lopes et al, 1993; Georgiadis et al, 1994) and docetaxel (Hill et al,
1994) exposure has a great impact on the growth-inhibitory effect
of the drug.
In fact, in studies combining taxanes and radiation, increasing
the time of exposure has been reported to be more important than
increasing the drug concentration (Schiff et al, 1995). In the
present study, the time of exposure was long and was kept
constant, and the interaction of cisplatin and taxanes was studied
as the function of drug concentrations.
The efficacy of the cisplatin–paclitaxel combination has been
demonstrated in clinical use. Incorporating paclitaxel into first-line
therapy has improved the survival in stage III and stage IV ovarian
carcinoma (McGuire et al, 1996; Piccart et al, 1997). The thera-
peutic effect of docetaxel–cisplatin combination is under investi-
gation. The results of the present study indicate that on a molar
basis the combination of docetaxel–cisplatin is more cytotoxic
than the combination of paclitaxel–cisplatin. If the toxicity profile
of the docetaxel–cisplatin combination is acceptable, a random-
ized trial comparing the two taxane–cisplatin combinations is
warranted.
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